-
Je něco špatně v tomto záznamu ?
Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial
HC. Mandeville, G. Bisogno, V. Minard-Colin, R. Alaggio, M. Ben-Arush, C. Chargari, B. Coppadoro, R. Craigie, C. Devalck, S. Ferman, A. Ferrari, H. Glosli, RH. Alvaro, M. Hol, P. Mudry, D. Orbach, MR. Albiac, JHM. Merks, MEM. Jenney
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie
Grantová podpora
Fondazione Città della Speranza
Alice's Arc Children's Cancer Charity
PubMed
39058728
DOI
10.1002/cncr.35497
Knihovny.cz E-zdroje
- MeSH
- daktinomycin * aplikace a dávkování terapeutické užití MeSH
- dítě MeSH
- ifosfamid * aplikace a dávkování MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- předškolní dítě MeSH
- prospektivní studie MeSH
- protokoly protinádorové kombinované chemoterapie * terapeutické užití MeSH
- rhabdomyosarkom * radioterapie terapie mortalita chirurgie farmakoterapie MeSH
- vinkristin * aplikace a dávkování terapeutické užití MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: The authors report the prospective evaluation of reduced dose alkylator chemotherapy combined with radiotherapy for European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) standard risk nonalveolar rhabdomyosarcoma (NA-RMS). PATIENTS AND METHODS: Localized node negative Intergroup Rhabdomyosarcoma Study (IRS) II/III NA-RMS at favorable sites (subgroup C), <25 years old, received five cycles of ifosfamide, vincristine, and dactinomycin (IVA) chemotherapy (30 g/m2 ifosfamide) and four cycles of vincristine and dactinomycin (if receiving radiotherapy), or nine cycles of IVA (54 g/m2 ifosfamide) ± radiotherapy. Delayed primary tumor excision was considered for IRS III tumors. The primary end points were event-free survival (EFS) and overall survival (OS). RESULTS: From October 2005 to December 2016, 359 evaluable patients were recruited: orbit, 164 (45.7%); head and neck nonparameningeal, 77 (21.4%); and genitourinary non-bladder/prostate, 118 (32.9%). EFS and OS were 77.4% (95% confidence interval [CI], 72.5-81.6) and 93.5% (95% CI, 90.1-95.8), respectively. Lower dose alkylator chemotherapy and radiotherapy achieved 5-year OS of 93.7% but the difference with higher dose alkylator chemotherapy +/- radiotherapy was not significant (p = 0.8003). Adjuvant radiotherapy improved EFS with 5-year estimates of 84.7% versus 65.2% for nonirradiated (p < .0001), but not OS (p = .9298). Omitting radiotherapy for orbital tumors reduced OS (5-year was 87.1% vs. 97.3% for irradiated, p = .0257). Following R0 resection (n = 60), radiotherapy did not significantly improve EFS or OS. CONCLUSIONS: Radiotherapy for local tumor control allows for reduction of cumulative dose of alkylators in EpSSG standard risk subgroup C RMS patients. The omission of radiotherapy did not affect OS in all patients except those with orbital RMS and was associated with inferior EFS.
Children's Hospital for Wales Heath Park Cardiff UK
Department of Paediatric Surgery Royal Manchester Children's Hospital Manchester UK
Department of Pediatric Oncology and Haematology Hospital Universitari Vall d'Hebron Barcelona Spain
Department of Radiotherapy Hospital Universitari Vall d'Hebron Barcelona Spain
Hôpital Universitaire des Enfants Reine Fabiola ULB Brussels Belgium
Paediatric Oncology Unit Fondazione IRCCS Istituto Nazionale Tumori Milano Italy
Pathology Unit Department of Laboratories Bambino Gesu Children's Hospital IRCCS Rome Italy
Pediatric Oncology Department National Cancer Institute Rio de Janeiro Brazil
Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands
Radiation Oncology Gustave Roussy Cancer Campus Villejuif France
SIREDO Oncology Center Institut Curie PSL University Paris France
The Royal Marsden Hospital and The Institute of Cancer Research Surrey UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003314
- 003
- CZ-PrNML
- 005
- 20250206104241.0
- 007
- ta
- 008
- 250121s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/cncr.35497 $2 doi
- 035 __
- $a (PubMed)39058728
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Mandeville, Henry C $u The Royal Marsden Hospital and The Institute of Cancer Research, Surrey, UK $1 https://orcid.org/0000000168208578
- 245 10
- $a Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial / $c HC. Mandeville, G. Bisogno, V. Minard-Colin, R. Alaggio, M. Ben-Arush, C. Chargari, B. Coppadoro, R. Craigie, C. Devalck, S. Ferman, A. Ferrari, H. Glosli, RH. Alvaro, M. Hol, P. Mudry, D. Orbach, MR. Albiac, JHM. Merks, MEM. Jenney
- 520 9_
- $a BACKGROUND: The authors report the prospective evaluation of reduced dose alkylator chemotherapy combined with radiotherapy for European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) standard risk nonalveolar rhabdomyosarcoma (NA-RMS). PATIENTS AND METHODS: Localized node negative Intergroup Rhabdomyosarcoma Study (IRS) II/III NA-RMS at favorable sites (subgroup C), <25 years old, received five cycles of ifosfamide, vincristine, and dactinomycin (IVA) chemotherapy (30 g/m2 ifosfamide) and four cycles of vincristine and dactinomycin (if receiving radiotherapy), or nine cycles of IVA (54 g/m2 ifosfamide) ± radiotherapy. Delayed primary tumor excision was considered for IRS III tumors. The primary end points were event-free survival (EFS) and overall survival (OS). RESULTS: From October 2005 to December 2016, 359 evaluable patients were recruited: orbit, 164 (45.7%); head and neck nonparameningeal, 77 (21.4%); and genitourinary non-bladder/prostate, 118 (32.9%). EFS and OS were 77.4% (95% confidence interval [CI], 72.5-81.6) and 93.5% (95% CI, 90.1-95.8), respectively. Lower dose alkylator chemotherapy and radiotherapy achieved 5-year OS of 93.7% but the difference with higher dose alkylator chemotherapy +/- radiotherapy was not significant (p = 0.8003). Adjuvant radiotherapy improved EFS with 5-year estimates of 84.7% versus 65.2% for nonirradiated (p < .0001), but not OS (p = .9298). Omitting radiotherapy for orbital tumors reduced OS (5-year was 87.1% vs. 97.3% for irradiated, p = .0257). Following R0 resection (n = 60), radiotherapy did not significantly improve EFS or OS. CONCLUSIONS: Radiotherapy for local tumor control allows for reduction of cumulative dose of alkylators in EpSSG standard risk subgroup C RMS patients. The omission of radiotherapy did not affect OS in all patients except those with orbital RMS and was associated with inferior EFS.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a rhabdomyosarkom $x radioterapie $x terapie $x mortalita $x chirurgie $x farmakoterapie $7 D012208
- 650 _2
- $a předškolní dítě $7 D002675
- 650 12
- $a vinkristin $x aplikace a dávkování $x terapeutické užití $7 D014750
- 650 12
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a kojenec $7 D007223
- 650 12
- $a ifosfamid $x aplikace a dávkování $7 D007069
- 650 _2
- $a prospektivní studie $7 D011446
- 650 12
- $a daktinomycin $x aplikace a dávkování $x terapeutické užití $7 D003609
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Bisogno, Gianni $u Hematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padova, Italy $1 https://orcid.org/0000000344625523
- 700 1_
- $a Minard-Colin, Veronique $u Department of Pediatric and Adolescent Oncology, INSERM U1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France $1 https://orcid.org/0000000202965207
- 700 1_
- $a Alaggio, Rita $u Pathology Unit, Department of Laboratories, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy
- 700 1_
- $a Ben-Arush, Myriam $u Ruth Rappaport Children's Hospital, Rambam Medical Center, Joan and Sanford Weill Pediatric Hematology Oncology and Bone Marrow Transplantation Division, Haifa, Israel
- 700 1_
- $a Chargari, Cyrus $u Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
- 700 1_
- $a Coppadoro, Beatrice $u Hematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padova, Italy
- 700 1_
- $a Craigie, Ross $u Department of Paediatric Surgery, Royal Manchester Children's Hospital, Manchester, UK
- 700 1_
- $a Devalck, Christine $u Hôpital Universitaire des Enfants Reine Fabiola ULB, Brussels, Belgium
- 700 1_
- $a Ferman, Sima $u Pediatric Oncology Department, National Cancer Institute, Rio de Janeiro, Brazil
- 700 1_
- $a Ferrari, Andrea $u Paediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy $1 https://orcid.org/0000000247240517
- 700 1_
- $a Glosli, Heidi $u Centre for Rare Disorders, Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
- 700 1_
- $a Alvaro, Raquel Hladun $u Department of Pediatric Oncology and Haematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- 700 1_
- $a Hol, Marinka $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $1 https://orcid.org/000000034926056X
- 700 1_
- $a Mudry, Peter $u Pediatric Oncology, Department University Hospital Brno and Faculty of Medicine Masaryk University, Brno, Czech Republic
- 700 1_
- $a Orbach, Daniel $u SIREDO Oncology Center, Institut Curie, PSL University, Paris, France $1 https://orcid.org/000000022520139X
- 700 1_
- $a Albiac, Monica Ramos $u Department of Radiotherapy, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- 700 1_
- $a Merks, Johannes H M $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
- 700 1_
- $a Jenney, Meriel E M $u Children's Hospital for Wales, Heath Park, Cardiff, UK
- 773 0_
- $w MED00001031 $t Cancer $x 1097-0142 $g Roč. 130, č. 23 (2024), s. 4071-4084
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39058728 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104237 $b ABA008
- 999 __
- $a ok $b bmc $g 2263211 $s 1239321
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 130 $c 23 $d 4071-4084 $e 20240726 $i 1097-0142 $m Cancer $n Cancer $x MED00001031
- GRA __
- $p Fondazione Città della Speranza
- GRA __
- $p Alice's Arc Children's Cancer Charity
- LZP __
- $a Pubmed-20250121
